Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

More Hysterectomies Could Be Performed With Minimally Invasive Techniques
Eighty percent of women who have a hysterectomy have a traditional one, in which a surgeon must make an extensive incision that runs from the navel to the top of the pubic bone. If only these women"s gynecologists had been trained in minimally invasive laparoscopic surgery techniques, many of them could have had hysterectomies involving just a few small, keyhole incisions. Also, their recovery time would have also been reduced drastically, permitting them to resume their normal lives much faster.
diet pills
Obesity And Migraine Sufferers More Emotionally Traumatized Than Those With Life-Threatening Conditions
Need another reason to commit to a healthy diet and exercise? Think migraines are just headaches? Migraine and obesity sufferers feel more emotional pain than those dealing with life-threatening conditions like congestive heart failure, prostate cancer, osteoporosis and high blood pressure. In fact, they tend to feel more pessimistic than those diagnosed with depression.
News of the day
What Is Endoscopy? What Is An Endoscope?
An endoscopy involves examining the inside of a person"s body using an endoscope. An endoscope is a medical device consisting of a long, thin, flexible (or rigid) tube which has a light and a video camera. Images of the inside of the patient"s body can be seen on a screen. The whole endoscopy is recorded so that doctors can check it again. Endoscopy is a minimally invasive diagnostic medical procedure. It is used to examine the interior surfaces of an organ or tissue.
Cardiovascular

UK Patients To Benefit From Access To Innovative Lung Cancer Treatment

The National Institute for Health and Clinical Excellence (NICE) have today published their recommendation for the use of the innovative chemotherapy pemetrexed (Alimta), in combination with cisplatin - a platinum based chemotherapy, as a 1st-line treatment for patients with adenocarcinoma or large-cell carcinoma non-small cell lung cancer* (NSCLC)1 within their Final Appraisal Determination (FAD). Final Guidance on the use of pemetrexed and cisplatin within this indication is anticipated to be published in September 2009 as a result of the FAD. Lilly welcomes this FAD decision which means that UK patients with adenocarcinoma and large cell carcinoma NSCLC are to benefit from publicly funded access to the combination as 1st line treatment. Lung cancer is the UK"s biggest cancer killer2 and the second most common cancer in the UK after breast cancer2, accounting for one in 20 of all deaths nationwide. Treatment with pemetrexed and cisplatin represents a significant development in non-squamous NSCLC treatment as it has shown to extend life beyond one year in certain patients**3. In addition, pemetrexed with cisplatin offers improved tolerability for non-squamous NSCLC patients3 when compared to the most widely prescribed treatment combination, gemcitabine and cisplatin. In clinical trials comparing the two treatment combinations, patients receiving pemetrexed and cisplatin required fewer transfusions, experienced lower incidence of neutropenia (a disorder leading to a low white blood cell count) and half the number of patients encountered hair loss.3 Professor Nick Thatcher, Professor in Medical Oncology at The Christie NHS Foundation Trust said: "This decision is truly significant and is fantastic news for lung cancer patients in the UK and the clinicians who have been campaigning for access. "It is NICE"s first FAD incorporating the use of histology. A histological diagnosis, the microscopic analysis of a tumour biopsy, allows the determination of exactly which type of NSCLC is present***, thereby allowing treatments to be more targeted and therefore more effective. "This "targeting" of patients has helped NICE confirm that pemetrexed and cisplatin is a clinically and cost effective treatment in patients with a confirmed diagnosis of adenocarcinoma or large-cell carcinoma." "The decision reflects the advancement pemetrexed in combination with cisplatin brings, with clinicians being able to target the right patients with the right treatment based on histological diagnosis. NICE should be commended on allowing UK patients to be the first to have funded access to this combination for the 1st line treatment of non-squamous NSCLC. "We now need to work hard to ensure that there is equitable access to this medicine throughout the UK." Pemetrexed and cisplatin are administered as an infusion every three weeks, providing an additional benefit of reducing the frequency of hospital visits and medication when compared with other treatments.4 The full FAD documentation can be found on the NICE website www.nice.org.uk. Final guidance on the use of pemetrexed and cisplatin for the 1st line treatment of locally advanced or metastatic non-squamous NSCLC is expected in September 2009 and will also be published on the NICE website. Notes * For patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ** In patients with adenocarcinoma *** Of the three types of NSCLC, pemetrexed has been shown to be more effective in two types, adenocarcinoma and large cell carcinoma (referred to as non-squamous NSCLC). These two types of NSCLC represent approximately 55% of all NSCLC cases References 1 - National Institute for Health and Clinical Excellence. Pemetrexed for the 1st line treatment of non-small cell lung cancer. Final Appraisal Determination: http://guidance.nice.org.uk/TA/Wave18/25 2 - Cancer Research, UK. Cancer Stats, Key Facts on Lung Cancer and Smoking. http://info.cancerresearchuk.org/cancerstats/types/lung/ (Accessed July 2009) 3 - Scaglotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol; 2008 Jul 20;26(21):3543-51. Epub 2008 May 27 4 - Alimta SmPC Eli Lilly and Company Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009